ESR1 and breast cancer: In this breast cancer cohort, 103 patients (54.5%) were ER + PR+, 72 patients (38.1%) were ER − PR−, 10 patients (5.3%) were ER − PR+, and 4 patients (2.1%) ER + PR−.